Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: An algorithm for the pre-emptive use of plerixafor

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Plerixafor "on demand" after chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) is efficient in peripheral stem cell mobilization, but the timing of administration and criteria for patient selection are under investigation. To devise an algorithm for the "on demand" use of plerixafor at the first mobilization attempt, we analyzed the kinetics of hematopoietic recovery and peripheral blood CD34+ cells in 107 patients treated with high-dose cyclophosphamide plus G-CSF. Fifty-one patients with myeloma were treated with cyclophosphamide 3-4 g/m2 on day 0 followed by G-CSF 10 ug/kg from day + 6, and 56 patients with lymphoma received cyclophosphamide 6-7 g/m2 followed by G-CSF 5 μg/kg from day +1. Peripheral blood CD34+ cell monitoring was started on day + 8 in patients with myeloma and day + 10 in patients with lymphoma. The outcome of interest was a collection of ≤ 2 × 106 CD34+/kg. By a multivariate logistic regression model, CD34+ cell count 1000/μL) or leukocyte count

Original languageEnglish
Pages (from-to)331-336
Number of pages6
JournalLeukemia and Lymphoma
Volume55
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Granulocyte Colony-Stimulating Factor
Cyclophosphamide
Blood Cells
Lymphoma
Logistic Models
Hematopoietic Stem Cell Mobilization
Leukocyte Count
Patient Selection
Cell Count
JM 3100
Drug Therapy

Keywords

  • Lymphoma
  • Myeloma
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{5ea692a21aab47caba5202b1b83e1d57,
title = "Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: An algorithm for the pre-emptive use of plerixafor",
abstract = "Plerixafor {"}on demand{"} after chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) is efficient in peripheral stem cell mobilization, but the timing of administration and criteria for patient selection are under investigation. To devise an algorithm for the {"}on demand{"} use of plerixafor at the first mobilization attempt, we analyzed the kinetics of hematopoietic recovery and peripheral blood CD34+ cells in 107 patients treated with high-dose cyclophosphamide plus G-CSF. Fifty-one patients with myeloma were treated with cyclophosphamide 3-4 g/m2 on day 0 followed by G-CSF 10 ug/kg from day + 6, and 56 patients with lymphoma received cyclophosphamide 6-7 g/m2 followed by G-CSF 5 μg/kg from day +1. Peripheral blood CD34+ cell monitoring was started on day + 8 in patients with myeloma and day + 10 in patients with lymphoma. The outcome of interest was a collection of ≤ 2 × 106 CD34+/kg. By a multivariate logistic regression model, CD34+ cell count 1000/μL) or leukocyte count",
keywords = "Lymphoma, Myeloma, Stem cell mobilization",
author = "Lucia Farina and Francesco Spina and Anna Guidetti and Paolo Longoni and Fernando Ravagnani and Anna Dodero and Vittorio Montefusco and Carmelo Carlo-Stella and Paolo Corradini",
year = "2014",
doi = "10.3109/10428194.2013.802783",
language = "English",
volume = "55",
pages = "331--336",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor

T2 - An algorithm for the pre-emptive use of plerixafor

AU - Farina, Lucia

AU - Spina, Francesco

AU - Guidetti, Anna

AU - Longoni, Paolo

AU - Ravagnani, Fernando

AU - Dodero, Anna

AU - Montefusco, Vittorio

AU - Carlo-Stella, Carmelo

AU - Corradini, Paolo

PY - 2014

Y1 - 2014

N2 - Plerixafor "on demand" after chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) is efficient in peripheral stem cell mobilization, but the timing of administration and criteria for patient selection are under investigation. To devise an algorithm for the "on demand" use of plerixafor at the first mobilization attempt, we analyzed the kinetics of hematopoietic recovery and peripheral blood CD34+ cells in 107 patients treated with high-dose cyclophosphamide plus G-CSF. Fifty-one patients with myeloma were treated with cyclophosphamide 3-4 g/m2 on day 0 followed by G-CSF 10 ug/kg from day + 6, and 56 patients with lymphoma received cyclophosphamide 6-7 g/m2 followed by G-CSF 5 μg/kg from day +1. Peripheral blood CD34+ cell monitoring was started on day + 8 in patients with myeloma and day + 10 in patients with lymphoma. The outcome of interest was a collection of ≤ 2 × 106 CD34+/kg. By a multivariate logistic regression model, CD34+ cell count 1000/μL) or leukocyte count

AB - Plerixafor "on demand" after chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) is efficient in peripheral stem cell mobilization, but the timing of administration and criteria for patient selection are under investigation. To devise an algorithm for the "on demand" use of plerixafor at the first mobilization attempt, we analyzed the kinetics of hematopoietic recovery and peripheral blood CD34+ cells in 107 patients treated with high-dose cyclophosphamide plus G-CSF. Fifty-one patients with myeloma were treated with cyclophosphamide 3-4 g/m2 on day 0 followed by G-CSF 10 ug/kg from day + 6, and 56 patients with lymphoma received cyclophosphamide 6-7 g/m2 followed by G-CSF 5 μg/kg from day +1. Peripheral blood CD34+ cell monitoring was started on day + 8 in patients with myeloma and day + 10 in patients with lymphoma. The outcome of interest was a collection of ≤ 2 × 106 CD34+/kg. By a multivariate logistic regression model, CD34+ cell count 1000/μL) or leukocyte count

KW - Lymphoma

KW - Myeloma

KW - Stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=84897960598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897960598&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.802783

DO - 10.3109/10428194.2013.802783

M3 - Article

C2 - 23656194

AN - SCOPUS:84897960598

VL - 55

SP - 331

EP - 336

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -